Cargando…

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses

Background: This study aimed to determine the optimal combination of biomarkers that can predict epithelial ovarian cancer (EOC) and compare the combination with the risk of ovarian malignancy algorithm (ROMA) or Copenhagen index (CPH-I). Methods: Data from 66 patients with EOC and 599 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Tae-Kyu, Kim, Heungyeol, Eo, Wankyu, Kim, Ki Hyung, Lee, Chul Min, Kim, Minyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088533/
https://www.ncbi.nlm.nih.gov/pubmed/37057288
http://dx.doi.org/10.7150/jca.81174
_version_ 1785022590320902144
author Jang, Tae-Kyu
Kim, Heungyeol
Eo, Wankyu
Kim, Ki Hyung
Lee, Chul Min
Kim, Minyoung
author_facet Jang, Tae-Kyu
Kim, Heungyeol
Eo, Wankyu
Kim, Ki Hyung
Lee, Chul Min
Kim, Minyoung
author_sort Jang, Tae-Kyu
collection PubMed
description Background: This study aimed to determine the optimal combination of biomarkers that can predict epithelial ovarian cancer (EOC) and compare the combination with the risk of ovarian malignancy algorithm (ROMA) or Copenhagen index (CPH-I). Methods: Data from 66 patients with EOC and 599 patients with benign ovarian masses who underwent definitive tissue diagnosis of adnexal masses between January 2017 and March 2021 were analyzed. The Mann-Whitney U test or Kruskal-Wallis test was used for between-group comparisons of medians. Logistic regression was used to establish an EOC predictor model. Area under the curve (AUC) comparisons between models were performed using the Delong nonparametric approach. Results: The median age of the patients was 43 years. Twenty-nine (43.9%) patients had early-stage disease (stages I-II) and 37 (56.1%) patients had advanced-stage disease (stages III-IV). The median age, body mass index, white blood cell count, hemoglobin-to-red cell distribution width ratio (HRR), platelet count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, serum albumin level, cancer antigen 125, human epididymal secretory protein 4 (HE4), ROMA, and CPH-I were significantly different between the stage I-IV EOC and benign ovarian mass groups. Multivariate logistic regression analysis revealed that HE4, HRR, and computed tomography (CT) imaging were significant predictors of both stages I-IV and I-II EOC. Using these covariates, an interim model (IM) (consisting of HE4 and HRR) and a full model (FM) (consisting of HE4, HRR, and CT imaging) were constructed. When predicting stage I-IV EOC, the AUC of IM was comparable to that of ROMA or CPH-I, whereas the AUC of FM outperformed ROMA or CPH-I. In predicting stage I-II EOC, the AUC of IM was comparable to that of CPH-I but higher than that of ROMA, and the AUC of FM outperformed ROMA or CPH-I. Conclusion: FM outperformed ROMA or CPH-I in predicting stage I-IV EOC and stage I-II EOC. Therefore, FM could be a promising model for improving preoperative prediction of EOC at an early stage. However, further prospective studies are required to validate these results.
format Online
Article
Text
id pubmed-10088533
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-100885332023-04-12 Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses Jang, Tae-Kyu Kim, Heungyeol Eo, Wankyu Kim, Ki Hyung Lee, Chul Min Kim, Minyoung J Cancer Research Paper Background: This study aimed to determine the optimal combination of biomarkers that can predict epithelial ovarian cancer (EOC) and compare the combination with the risk of ovarian malignancy algorithm (ROMA) or Copenhagen index (CPH-I). Methods: Data from 66 patients with EOC and 599 patients with benign ovarian masses who underwent definitive tissue diagnosis of adnexal masses between January 2017 and March 2021 were analyzed. The Mann-Whitney U test or Kruskal-Wallis test was used for between-group comparisons of medians. Logistic regression was used to establish an EOC predictor model. Area under the curve (AUC) comparisons between models were performed using the Delong nonparametric approach. Results: The median age of the patients was 43 years. Twenty-nine (43.9%) patients had early-stage disease (stages I-II) and 37 (56.1%) patients had advanced-stage disease (stages III-IV). The median age, body mass index, white blood cell count, hemoglobin-to-red cell distribution width ratio (HRR), platelet count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, serum albumin level, cancer antigen 125, human epididymal secretory protein 4 (HE4), ROMA, and CPH-I were significantly different between the stage I-IV EOC and benign ovarian mass groups. Multivariate logistic regression analysis revealed that HE4, HRR, and computed tomography (CT) imaging were significant predictors of both stages I-IV and I-II EOC. Using these covariates, an interim model (IM) (consisting of HE4 and HRR) and a full model (FM) (consisting of HE4, HRR, and CT imaging) were constructed. When predicting stage I-IV EOC, the AUC of IM was comparable to that of ROMA or CPH-I, whereas the AUC of FM outperformed ROMA or CPH-I. In predicting stage I-II EOC, the AUC of IM was comparable to that of CPH-I but higher than that of ROMA, and the AUC of FM outperformed ROMA or CPH-I. Conclusion: FM outperformed ROMA or CPH-I in predicting stage I-IV EOC and stage I-II EOC. Therefore, FM could be a promising model for improving preoperative prediction of EOC at an early stage. However, further prospective studies are required to validate these results. Ivyspring International Publisher 2023-02-27 /pmc/articles/PMC10088533/ /pubmed/37057288 http://dx.doi.org/10.7150/jca.81174 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Jang, Tae-Kyu
Kim, Heungyeol
Eo, Wankyu
Kim, Ki Hyung
Lee, Chul Min
Kim, Minyoung
Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title_full Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title_fullStr Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title_full_unstemmed Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title_short Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses
title_sort clinical significance of the combination of serum he4 levels, hemoglobin-to-red cell distribution width ratio, and ct imaging for the pretreatment assessment of adnexal masses
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088533/
https://www.ncbi.nlm.nih.gov/pubmed/37057288
http://dx.doi.org/10.7150/jca.81174
work_keys_str_mv AT jangtaekyu clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses
AT kimheungyeol clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses
AT eowankyu clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses
AT kimkihyung clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses
AT leechulmin clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses
AT kimminyoung clinicalsignificanceofthecombinationofserumhe4levelshemoglobintoredcelldistributionwidthratioandctimagingforthepretreatmentassessmentofadnexalmasses